162 related articles for article (PubMed ID: 35490254)
1. Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.
Xu C; Minaguchi T; Qi N; Fujieda K; Suto A; Itagaki H; Shikama A; Tasaka N; Akiyama A; Nakao S; Ochi H; Satoh T
World J Surg Oncol; 2022 Apr; 20(1):139. PubMed ID: 35490254
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
4. Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.
Robello M; Zheng H; Saha M; George Rosenker KM; Debnath S; Kumar JP; Tagad HD; Mazur SJ; Appella E; Appella DH
Eur J Med Chem; 2022 Dec; 243():114763. PubMed ID: 36179402
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma.
Sun GG; Zhang J; Ma XB; Wang YD; Cheng YJ; Hu WN
Pathol Oncol Res; 2015 Apr; 21(2):283-91. PubMed ID: 25060857
[TBL] [Abstract][Full Text] [Related]
6. A novel assay for screening WIP1 phosphatase substrates in nuclear extracts.
Storchova R; Burdova K; Palek M; Medema RH; Macurek L
FEBS J; 2021 Oct; 288(20):6035-6051. PubMed ID: 33982878
[TBL] [Abstract][Full Text] [Related]
7. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas.
Liang C; Guo E; Lu S; Wang S; Kang C; Chang L; Liu L; Zhang G; Wu Z; Zhao Z; Ma S; Wang L; Jiao BH
Brain Res; 2012 Mar; 1444():65-75. PubMed ID: 22325093
[TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC.
Yang S; Dong S; Qu X; Zhong X; Zhang Q
Mol Med Rep; 2017 Feb; 15(2):719-723. PubMed ID: 27959454
[TBL] [Abstract][Full Text] [Related]
11. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
Brazina J; Svadlenka J; Macurek L; Andera L; Hodny Z; Bartek J; Hanzlikova H
Cell Cycle; 2015; 14(3):375-87. PubMed ID: 25659035
[TBL] [Abstract][Full Text] [Related]
12. The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia.
Tan B; Tong C; Yuan Y; Xu P; Wen L; Zhang C; Zheng Y; Lin L; Zhu F; Gui S; Wang L; Gao R; Li J; Qi H; Baker PN
Cell Physiol Biochem; 2019; 52(2):315-335. PubMed ID: 30816677
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma.
Chen M; Wang W; Hu S; Tong Y; Li Y; Wei Q; Yu L; Zhu L; Zhu Y; Liu L; Ju Z; Wang X; Jin H; Feng L
Cell Commun Signal; 2022 Mar; 20(1):39. PubMed ID: 35346236
[TBL] [Abstract][Full Text] [Related]
15. Wip1 phosphatase: between p53 and MAPK kinases pathways.
Goloudina AR; Kochetkova EY; Pospelova TV; Demidov ON
Oncotarget; 2016 May; 7(21):31563-71. PubMed ID: 26883196
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent mutual regulation between Wip1 and p53 following UVC irradiation.
Xia Y; Yang Q; Gong X; Ye F; Liou YC
Int J Biochem Cell Biol; 2011 Apr; 43(4):535-44. PubMed ID: 21163364
[TBL] [Abstract][Full Text] [Related]
17. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.
Schito ML; Demidov ON; Saito S; Ashwell JD; Appella E
J Immunol; 2006 Apr; 176(8):4818-25. PubMed ID: 16585576
[TBL] [Abstract][Full Text] [Related]
18. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Crescenzi E; Raia Z; Pacifico F; Mellone S; Moscato F; Palumbo G; Leonardi A
J Biol Chem; 2013 Jun; 288(23):16212-16224. PubMed ID: 23612976
[TBL] [Abstract][Full Text] [Related]
20. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
